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Abstract
Work from our laboratory and others has demonstrated that activation of the nuclear receptor peroxisome proliferator–
activated receptor-γ (PPARγ) inhibits transformed growth of non–small cell lung cancer (NSCLC) cell lines in vitro and
in vivo. We have demonstrated that activation of PPARγ promotes epithelial differentiation of NSCLC by increasing ex-
pression of E-cadherin, as well as inhibiting expression of COX-2 and nuclear factor-κB. The Snail family of transcription
factors, which includes Snail (Snail1), Slug (Snail2), and ZEB1, is an important regulator of epithelial-mesenchymal transi-
tion, as well as cell survival. The goal of this study was to determine whether the biological responses to rosiglitazone, a
memberof the thiazolidinedione family of PPARγactivators, aremediated through the regulationof Snail familymembers.
Our results indicate that, in two independent NSCLC cell lines, rosiglitazone specifically decreased expression of Snail,
with no significant effect on either Slug or ZEB1. Suppression of Snail using short hairpin RNA silencing mimicked the
effects of PPARγ activation, in inhibiting anchorage-independent growth, promoting acinar formation in three-dimensional
culture, and inhibiting invasiveness. This was associated with the increased expression of E-cadherin and decreased
expression of COX-2 andmatrix metaloproteinases. Conversely, overexpression of Snail blocked the biological responses
to rosiglitazone, increasing anchorage-independent growth, invasiveness, and promoting epithelial-mesenchymal transi-
tion. The suppression of Snail expression by rosiglitazone seemed to be independent of GSK-3 signaling but was rather
mediated through suppression of extracellular signal–regulated kinase activity. These findings suggest that selective
regulation of Snail may be critical in mediating the antitumorigenic effects of PPARγ activators.
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Introduction
A considerable amount of current literature suggests that loss of epithe-
lial features and gain of mesenchymal properties play a critical role in
the progression and metastasis of epithelial tumors [1]. These events
are similar to the epithelial-mesenchymal transition (EMT) that has
been well characterized in embryonic development. EMT involves
complex cellular changes including loss of polarity and disruption of
cell-cell contacts, synthesis of extracellular matrix molecules, as well as
proteolytic enzymes such asmatrixmetalloproteinases (MMPs) involved
in matrix degradation that contribute to cell motility and invasiveness
[2]. Loss of E-cadherin has been shown to be associated with increased
tumor invasiveness, metastasis, and poor prognosis [3–5]. Transcrip-
tional repression has emerged as a mechanism of silencing E-cadherin
during tumor progression. This suppression is mediated by members
of the Snail, ZEB, and basic-helix-loop-helix families of transcription
factors. Snail1 (Snail) and Snail2 (Slug) belong to the Snail superfamily
of zinc finger transcriptional repressors that participate in the devel-
opmental EMT [6]. Snail is required for mesoderm and neural crest
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formation during embryonic development and has been implicated
in the EMT associated with tumor progression. Slug also represses
E-cadherin and induces a complete EMT. However, Slug binds with
lower affinity than Snail to the E-cadherin promoter [7].
Expression of Snail and/or Slug has been reported in breast, ovarian,
colon, skin, and squamous cell carcinomas and is associated with poor
prognosis [6,8]. Although the function of Snail and Slug can be inter-
changeable in different species [9], a distinct role for each factor is
supported from analysis of knockout mice. Whereas Snail null mice
present early embryonic lethality [10], Slug null mice are viable, under-
going a normal program of development [11]. The specific contribu-
tion of Snail and Slug to tumor progression is still poorly defined. Snail
is activated at the invasive front of tumors induced in mouse skin [12]
and has been associated with breast and hepatocarcinoma invasion
[13,14]. Snail induces a full EMT when overexpressed in epithelial
Madin-Darby canine kidney cells leading to acquisition of a motile/
invasive phenotype [12,15]. Recently, these transcription repressors have
also been found to be expressed in lung adenocarcinomas. Knockdown
of Snail, through RNA interference, increases the sensitivity of non–
small cell lung cancer (NSCLC) cells to chemotherapeutic agents [16].
Prostaglandin E2 has been shown to induce ZEB-1 and Snail in NSCLC
[17]. Slug expression is a predictor of outcome in lung adenocarcinoma
patients [18]. Overexpression of ZEB-1 has been implicated in mediat-
ing EMT in NSCLC cells [19].
Peroxisome proliferator–activated receptor-γ (PPARγ) is a mem-
ber of the nuclear receptor superfamily of ligand-activated transcription
factors. In addition to its known role in adipocyte differentiation,
PPARγ has been implicated in regulating carcinogenesis [20]. PPARγ
activators of the thiazolidinedione class (TZDs), such as rosiglitazone
and troglitazone, slow growth of colon and thyroid tumors [21,22].
In NSCLC, activation of PPARγ can inhibit growth of NSCLC cells
in vitro and in xenograft models [23–25]. We have shown that mice
with targeted overexpression of PPARγ in the distal epithelia of the
lung are protected against developing lung tumors in a chemical carcino-
genesis model [26].
Mechanistically, several studies have demonstrated that PPARγ acti-
vation can inhibit nuclear factor-κB and COX-2 expression in NSCLC
[26,27]. PPARγ has been shown to increase E-cadherin expression,
suggesting that it may target transcriptional repressors; however, the
effects of PPARγ on Snail family members have not been well studied.
Here, we report that PPARγ-mediated inhibition of Snail expression
represents a critical pathway in mediating the antitumorigenic effects
of TZDs on NSCLC.
Materials and Methods
Materials
Antibodies against Snail, Slug, extracellular signal–regulated kinases
(ERKs), phospho (p)-ERKs, GSK-3β, and p-GSK-3β were from Cell
Signaling Technology (Beverly, MA); antibody against E-cadherin was
from BD Biosciences (Franklin Lakes, NJ); and COX-2 antibody was
from Cayman Chemical (Ann Arbor, MI). β-Actin antibody was from
Sigma-Aldrich (St Louis, MO). Rosiglitazone was from Cayman Chemi-
cal (Ann Arbor, MI). PD98059 and GSK-3β inhibitors were from
Calbiochem (SanDiego,CA). All other reagents were fromSigma-Aldrich.
Cell Culture and Stable Transfections
Human lung adenocarcinoma cell lines, H2009 and H2122, were
obtained from the University of Colorado Health Science Center Tis-
sue Culture Core. The Snail complementary DNA (cDNA) was used to
stably transfect NSCLC by retroviral-mediated gene transfer as previ-
ously described [28]. Pools of stable transfectants were screened for
the expression of Snail by immunoblot analysis. Snail and control short
hairpin RNA (shRNA) plasmids obtained from Open Biosystems
(Rockford, IL) were used to transfect NSCLC using ExGen500 trans-
fection reagent (Fermentas, Glen Burnie, MD).
Migration/Invasion, Soft Agar Colony Formation, and
Three-dimensional Culture
Migration and invasion were determined as previously described
[23]. Colony formation in soft agar was performed as described pre-
viously [28]. Colonies formed in 3- to 4-week period were stained with
nitroblue tetrazolium chloride (1 mg/ml), visualized under a micro-
scope and counted. For three-dimensional cultures, cells were grown
in Matrigel using a modification of the procedure of Debnath et al.
[29], as previously described [23]. Briefly, cells were plated at 5000
per well in 10% Matrigel in full media and were fed with 4% every
other day for a term of 8 to 10 days of culture.
Confocal Microscopy and Image Analysis
Cells grown in two-dimensional or three-dimensional cultures were
fixed in 2% paraformaldehyde in phosphate-buffered saline for 30 min-
utes at room temperature. Cells were permeabilized with 0.5% Triton
X-100 for 15 minutes if needed. All samples were blocked with 1%
BSA in phosphate-buffered saline for 1 hour at room temperature. Cells
were incubated with E-cadherin antibody (1:100; BD Biosciences) for
three-dimensional cultures or anti-Snail antibodies (Santa Cruz Bio-
technology, Santa Cruz, CA) for two-dimensional cultures, overnight
at 4°C, followed by 1 hour of incubation with the appropriate secondary
antibodies (Alexa Fluor 568 rabbit antigoat immunoglobulin G, 1:250;
Invitrogen, Carlsbad, CA). Slides were mounted and viewed with
TE2000-S IF microscope (Nikon, Tokyo, Japan) or a 510 Meta/FCS
laser scanning confocal microscope (Carl Zeiss, Thornwood, NY). Con-
focal images were processed using LSM Image Examiner.
SYBR Green Real-time Reverse Transcription–Polymerase
Chain Reaction
Total RNAwas extracted from cell cultures using RNeasy kit (Qiagen,
Inc, Valencia, CA). cDNA was synthesized using iSCRIPT cDNA syn-
thesis kit from BioRad (BioRad, Hercules, CA). For real-time PCR,
relative gene expression was determined by SYBR Green JumpStart
Taq ReadyMix (Sigma) on a Bio-Rad iCycler (BioRad). Primer pairs
and PCR conditions are as follows: SnailF, 5′-CGCGCTCTTTCCT-
CGTCAG-3′; SnailR 5′-TCCCAGATGAGCATTGGCAG-3′; SlugF,
5′-GCCTCCAAAAAGCCAAACTA-3′; SlugR, 5′-CACAGT-
GATGGGGCTGATG-3′; ZEB1F, 5′-AGGAGTGAAAGAGAAGG-
GAATGC-3′; ZEB1R, 5′-GGTCCTCTTCAGGTGCCTCAG3′;
β-ActinF, 5′-AGGGTGTGATGGTGGGTATGG-3′; β-ActinR, 5′-
AATGCCGTGTTCAATGGGG-3′, 55 cycles at 95°C for 15 seconds,
60°C for 1 minute, and 72°C for 30 seconds; MMP-9F, 5′-CCACTT-
CCCCTTCATCTTC-3′; MMP-9R, 5′-CGTCCTGGGTGTA-
GAGTC-3′; 55 cycles at 95°C for 20 seconds, 60°C for 30 seconds,
and 72°C for 30 seconds; MMP-2F, 5′-TCTTGACCAGAATAC-
CATCG-3′; MMP-2R, 5′-CACATCGCTCCAGACTTG-3′; 55 cycles
at 95°C for 20 seconds, 58°C for 30 seconds, and 72°C for 30 seconds.
The relative gene expression, normalized to β-actin and based on three
separate experiments, was calculated.
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Matrix Metalloproteinase—Zymography
Semiconfluent cultures of cells (∼80% confluent) were placed in
serum-free medium, treated with or without rosiglitazone, and cultured
for an additional 36 hours. Conditioned medium was concentrated
(Microcon YM-10 centrifugal filter; Millipore, Billerica, MA) and sepa-
rated on 7% SDS–polyacrylamide gel containing 0.1% (wt./vol.) gelatin
under nonreducing conditions. Zymography for MMP-9 and MMP-2
was performed according to Bernhard and Muschel [30].
Statistical Analysis
Data are expressed as mean ± SEM of at least three independent ex-
periments. Statistical significance was determined by analyzing the data
using one-way analysis of variance (GraphPad InStat 3 Software). P <
.05 was considered statistically significant.
Results
PPARγ Selectively Inhibits Expression of Snail in NSCLC
To begin to define the molecular mechanisms whereby PPARγ can
control EMT in NSCLC, we examined the effects of the PPARγ acti-
vator rosiglitazone on transcriptional repressors of E-cadherin: Snail,
Slug, and ZEB1 in two lung adenocarcinoma cell lines, H2009 and
H2122. Stimulation with rosiglitazone (10 μM) decreased the expres-
sion of Snail in a time-dependent manner. Expression was significantly
decreased at 6 hours; by 24 hours, the expression was inhibited in both
cell lines by approximately 75% (Figure 1A, left panel ). No significant
changes were observed in expression of Slug (Figure 1A, right panel ).
Levels of messenger RNA (mRNA) for Snail, Slug, and ZEB1 were as-
sessed by real-time reverse transcription–polymerase chain reaction
(RT-PCR). Rosiglitazone significantly decreased Snail mRNA levels
in both cell lines; no significant effect was observed on expression of
either ZEB1 or Slug (Figure 1B). These findings were further confirmed
by reporter assays, wherein cells were transiently transfected with
Snail, Slug, and ZEB1 promoter constructs driving a luciferase reporter.
Rosiglitazone inhibited Snail promoter activity in both cell lines (Fig-
ure 1C ) but had no effect on either Slug or ZEB promoter activity.
To confirm if the effects on Snail expression were PPARγ specific, we
also examined Snail expression in H2122 cells overexpressing PPARγ.
Expression was markedly decreased in these cells compared with con-
trols transfected with empty vector (Figure 1D). No change in Slug ex-
pression was observed (Figure 1D). Finally, a pharmacological inhibitor
of PPARγ, T0070907 (T007) [31], was able to reverse the decrease in
Snail mRNA induced by rosiglitazone (Figure W1).
Snail Silencing Mimics Effects of PPARγ Activation on
Downstream Effectors
To assess the role that decreased expression of Snail plays in mediat-
ing the effects of PPARγ, we silenced Snail in both adenocarcinoma
cell lines. Cells were transfected with lentiviral vectors encoding shRNA
against Snail or with nonsilencing control shRNA (NS). Pools of cells
transfected with two independent Snail shRNA constructs (A12 and
E8) showed decreased expression of Snail protein compared with NS
controls in both cell lines (Figure 2A). A third shRNA construct (B9)
did not significantly decrease Snail expression in either cell line. In
addition, Snail promoter activity was also decreased in the silenced
cells compared with NS controls (data not shown). We have previ-
ously reported that overexpression of PPARγ increases E-cadherin
levels in NSCLC [23]. Here, we examined the effects of rosiglitazone
on E-cadherin expression. As shown in Figure 2B (top panels, left)),
rosiglitazone increased E-cadherin expression in both H2122 and
H2009. Silencing of Snail expression also resulted in increased E-cadherin
expression (Figure 2B, top panels, right). In both H2122 and H2009,
rosiglitazone decreased COX-2 expression, and this was also observed
in the cells silenced for Snail expression (Figure 2B, bottom panels).
Silencing Snail Mimics Biological Responses to Rosiglitazone
Consistent with the work of other investigators [25], exposure to
rosiglitazone inhibited soft agar colony formation, a measure of trans-
formed growth in both NSCLC cell lines (Figure 2C , left panel, top).
Importantly, silencing Snail using two independent shRNA constructs
(A12 and E8), also resulted in a marked decrease in colony formation
(Figure 2C , right panel, top). Rosiglitazone decreased invasion of
H2122 cells and inhibited both migration and invasion of H2009 cells
(Figure 2C). Silencing Snail expression similarly decreased migration
(Figure 2C , right panel, middle) and invasion (Figure 2C , right panel,
bottom) in both cell lines compared with NS cells. Finally, we exam-
ined the growth of NSCLC in three-dimensional Matrigel cultures.
Our previous studies demonstrated that H2122 cells form loose dis-
organized aggregates in three-dimensional culture (Figure 2D, panel a)
and that overexpression of PPARγ promotes formation of regular acinar-
like structures [23]. Treatment of NSCLC with rosiglitazone also led
to the formation of organized structures (Figure 2D, panel b). Cells si-
lenced for Snail expression also formed ordered structures that were
indistinguishable from those observed with rosiglitazone (Figure 2D,
panel d ), whereas NS controls formed structures analogous to wild-type
cells (Figure 2D, panel c).
Because MMPs are important in promoting invasion through the
extracellular matrix and are involved in tumor invasion and progression
[32], we determined whether the decreased migratory and invasive
properties of cells in response to PPARγ activation or silencing of Snail
were associated with changes in the activity or expression of MMPs. As
shown in Figure 3A (top panel ), rosiglitazone markedly decreased the
mRNA expression of MMP-9 in H2122 cells and modestly decreased
the expression in H2009 cells. No significant effects were seen on
MMP-2 expression (Figure 3A, bottom panel ). By zymography, expo-
sure to rosiglitazone was associated with a marked decrease in the ac-
tivity of both MMP-9 and MMP-2 in both cell lines (Figure 3C , left
panel ), indicating that PPARγ activation of MMPs involves additional
posttranscriptional mechanisms. Silencing of Snail had similar effects
in both cell lines. Levels of MMP-9 were decreased in both cell lines
(Figure 3B, top panel ), with minimal effects on MMP-2 mRNA (Fig-
ure 3B, bottom panel ) compared with NS controls. Zymography indi-
cated that silencing Snail selectively decreased MMP-9 in H2122 cells
while modestly decreasing both MMP-9 and MMP-2 in H2009 cells
(Figure 3C , right panel ).
Snail Overexpression Blocks Biological Responses
to Rosiglitazone
To complement the studies silencing expression Snail in NSCLC,
we stably overexpressed the protein in the two NSCLC cell lines. Mul-
tiple clones of stably transfected cells were selected by immunoblot
analysis. As shown in Figure 4A, cells transfectants showed an in-
crease in Snail protein expression compared with empty vector controls,
and expression was largely localized to the nucleus (Figure 4B). As
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expected, Snail-overexpressing cells had lower levels of E-cadherin pro-
tein (Figure 4C ) and decreased E-cadherin promoter activity (data
not shown). Rosiglitazone reduced Snail expression in the empty vec-
tor controls but had no effect on Snail expression in the overexpressing
cell lines.
In two independent clones of H2122 cells, Snail-overexpressing
cells showed a marked increase in colony formation in soft agar com-
pared with empty vector control (Figure 5A, top). In H2009, there was
a more modest but still statistically significant increase (Figure 5A, top
right). Importantly, whereas rosiglitazone decreased colony formation
Figure 1. Rosiglitazone selectively decreases expression of Snail in NSCLC. (A) Left panel: H2122 or H2009 cells treated with rosiglitazone
or vehicle (0.1% DMSO) for the indicated times were immunoblotted for Snail expression. Levels of β-actin were used as a loading control.
Right panel: Nuclear extracts from cells treated for 24 hourswith rosiglitazonewere immunoblotted for Slug. (B) RNAwas isolated from cells
stimulated for 24 hours with rosiglitazone or vehicle (0.1%DMSO), and the expression of Snail (left panel), Slug (middle panel), or ZEB1 (right
panel) was determined by real-time PCR. (C) Cells were transiently transfected with constructs encoding either the Snail promoter, the Slug
promoter, or the ZEB1 promoter, ligated to a luciferase reporter, along with a plasmid encoding β-gal under the control of CMV promoter to
normalize for transfection efficiency. Cells were stimulated with rosiglitazone for 24 hours, and luciferase activity normalized to β-gal activ-
ity was determined. Results are presented as percent of control for each promoter. **P< .01 versus controls, ***P< .001 versus controls.
All data represent the means of three independent experiments. (D) H2122 cells overexpressing PPARγ (H2122-PPARγ) or empty vector
(H2122-LNCX) were grown under standard conditions. Nuclear extracts were prepared as described inMaterials andMethods and immuno-
blotted for Snail (left panel) or Slug (right panel) expression. Levels of β-actin were used as a loading control. Results are representative of
three independent experiments.
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in empty vector cells, it had no effect on the colony number in Snail-
overexpressing cells. In both cell lines, overexpression of Snail increased
both migration and invasiveness (Figure 5A, middle and lower panels).
Whereas rosiglitazone decreased migration and invasiveness in H2009
cells, and selectively inhibited invasion of H2122 cells, similar to what
is observed in parental untransfected cells, it had no effect in either
cell line overexpressing Snail. Overexpression of Snail also increased
expression of both MMP-9 and MMP-2, and rosiglitazone did not
alter expression (Figure 5B). Finally, we examined the growth of Snail-
overexpressing cells in three-dimensional Matrigel cultures using
H2122 cells. Cells transfected with empty vector (L1) formed irregular
clusters of cells similar to those seen in untransfected cells (Figure 5C ,
upper left), and rosiglitazone promoted formation of regular acinar
structure (Figure 5C , upper right). In contrast, overexpression of Snail
Figure 2. (continued).
Figure 2. Silencing Snail expression recapitulates the responses to Rosiglitazone. (A) The indicated cell lines were stably transfected
with three distinct shRNA constructs against Snail, as well as a nonsilencing control construct (NS), and immunoblotted for Snail. Two of
the constructs (A12 and E8) effectively decreased the expression of Snail and were used in further experiments. (B) Left panels: NSCLCs
were stimulated for 24 hours with 10 μM rosiglitazone and immunoblotted for E-cadherin (top) or COX-2 (bottom). Right panel: Cells
silenced for the expression of Snail (E8), or nonsilencing control cells (NS) were immunoblotted for E-cadherin expression (top) or COX-2
(bottom). (C) Left panel, top: NSCLCs were plated in soft agar (0.3%), with or without rosiglitazone (10 μM), and the resulting colonies
were counted after 3 to 4 weeks. Right panel, top: Pooled cells silenced for Snail, or nonsilencing control cells were plated in soft agar
and the resulting colonies were counted. ***P < .001 versus controls or nonsilencing controls, *P < .05 versus nonsilencing controls.
Migration of NSCLC was assayed in Transwell chambers. Parental cells, with or without rosiglitazone (10 μM) treatment, or cells silenced for
the expression of Snail (A12 and E8), or nonsilencing control cells (NS) (middle panels), were placed 0.1% FBS with 5% FBS in the bottom
chamber. After 24 hours, migrating cells were stained with 4′,6-diamidino-2 phenylindole. **P< .01 versus controls or nonsilencing controls.
Invasion was measured using Transwell chambers coated with Matrigel (bottom panels). Cells were plated as previously mentioned and
counted at 72 hours. *P < .05 versus controls, **P < .01 versus controls or nonsilencing controls. (D) Untransfected H2122 cells and
H2122-NS and H2122-E8 cells were grown in three-dimensional Matrigel culture as described in Materials and Methods for 8 to 10 days.
H2122 cells were treated with rosiglitazone (10 μM). Cells were fixed and stained for E-cadherin expression (green) or 4′,6-diamidino-2 phenyl-
indole (blue). Representative acinar structures are shown. H2122 cells treatedwith rosiglitazone (b) formed regular acinar structures compared
with controls (a). Similarly, Snail-silenced cells (d) were characterized by a highly differentiated morphology compared with nonsilencing con-
trol cells (c).
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promoted more scattered structures and seemed to decrease cell ag-
gregation (Figure 5C , lower left). Rosiglitazone, in the setting of Snail
overexpression, failed to alter the structures and did not result in forma-
tion of regular acini (Figure 5C , lower right).
Effects of Rosiglitazone on Snail Are Mediated through
Suppression of ERK Activity
Whereas PPARγ activation can impact numerous signaling pathways,
a recent study demonstrated that troglitazone, another TZD mediates
induction of E-cadherin through the inhibition of mitogen-activated pro-
tein kinase (MAPK)/ERK signaling in pancreatic cancer cells [33]. We
therefore examined the effects of rosiglitazone on ERK activation in
H2122 and H2009 cells. Rosiglitazone decreased phospho-ERK expres-
sion in a time-dependent fashion, withmaximal decreases observed after
24 hours (Figure 6A). There was no significant change in total ERK ex-
pression. To determine whether this decrease in ERK mediated the de-
crease in Snail expression, cells were treated with the MEK inhibitor
PD98059, in the absence or presence of rosiglitazone. After 24 hours
of treatment, PD98059 and rosiglitazone both decreased the expression
of Snail in the two lung cancer cell lines to the same extent (Figure 6B);
combinations of rosiglitazone and PD98059 did not result in greater in-
hibition than either agent alone. Several studies have reported regulation
of Snail expression by GSK-3β, which is regulated through Wnt signal-
ing [34,35]. However, this pathway does not seem to play a major role
in the regulation of Snail by rosiglitazone because levels of phospho–
GSK-3β were not altered in response to rosiglitazone (Figure W2A),
and a GSK-3β inhibitor had no effect on the ability of rosiglitazone to
suppress Snail expression (Figure W2B).
Discussion
NSCLC, the most common cancer in the United States, is associated
with a poor prognosis, indicating that novel therapeutic approaches are
urgently needed. TZDs exhibit in vitro and in vivo antitumor effects
against many types of cancers, including lung cancer [36,37]. Analysis
of human lung tumors has reported that decreased expression of
PPARγ is correlated with a poor prognosis [38], and expression of
PPARγ as detected by immunohistochemistry was more frequently
detected in well-differentiated adenocarcinomas compared with poorly
Figure 3. PPARγ or Snail silencing inhibiting matrix metalloproteinases. (A) NSCLCs were treated with rosiglitazone (10 μM) or vehicle
(control) for 24 hours. Total RNA was isolated, and the expression of MMP-9 and MMP-2 mRNA normalized to β-actin was determined
by quantitative RT-PCR. Data are representative of three independent experiments. ***P< .001 versus controls. (B) Total RNAwas extracted
from Snail-silenced cells (E8) as well as nonsilencing control cells (NS). mRNA expression of MMP-9 andMMP-2 was analyzed as described
previously. ***P< .001 versus nonsilencing controls, **P< .01 versus nonsilencing controls. (C)Medium collected fromNSCLC treatedwith
or without rosiglitazone (left panel) or Snail-silenced cells (E8) and nonsilencing control cells (NS) (right panel) was assessed for MMP-9 and
MMP-2 activity as described in Materials and Methods.
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differentiated ones. Recently, a retrospective study demonstrated a 33%
reduction in lung cancer risk in patients with diabetes using the TZD
rosiglitazone [39]. This decreased risk seemed to be specific for lung
cancer because no protective effect was observed for prostate or colon
cancer. Genetic variants in the PPARγ gene, which are associated with a
decreased risk for lung cancer, have been identified [40]. These studies
strongly suggest the potential for TZDs as chemopreventive or chemo-
therapeutic agents for the treatment of lung cancer.
Previous work form our laboratory has demonstrated that activation
of PPARγ in NSCLC inhibits transformed growth, promotes differ-
entiation, and inhibits invasiveness [23,26,28]. However, the molecular
targets of PPARγ mediating these responses are not well defined. In
this study, we hypothesized that inhibitory effects of PPARγ on trans-
formed growth might be mediated by the down-regulation of Snail
family members. Activation of PPARγ by rosiglitazone in two NSCLC
cell lines decreased expression of Snail but did not significantly alter
expression of either Slug or ZEB1. Regulation of Snail expression seems
to be a critical event in mediating the effects of PPARγ on these cancer
cells. Cells with silenced expression of Snail recapitulated many of the
biological responses seen with rosiglitazone stimulation: inhibition of
anchorage-independent growth, inhibition of invasiveness, and promo-
tion of organized, more differentiated structures in three-dimensional
Figure 4. Overexpression of Snail inhibits the effects of rosiglitazone. (A) Snail-overexpressing clones (S9 for H2122 and S1 for H2009) and
empty vector controls (L4 and L2) were treated with or without rosiglitazone (10 μM) for 24 hours, and Snail expression was determined
by immunoblot analysis. (B) Transfected cells were immunostained with anti-Snail antibody. (C) Lysates from the indicted cell lines were
immunoblotted for E-cadherin. Data are representative of three independent experiments.
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culture. Conversely, overexpression of Snail was sufficient to block the
action of rosiglitazone on all of these responses.
Snail suppression increased levels of E-cadherin and decreased lev-
els of MMPs in NSCLC. Inhibition of MMP expression is likely to
account, at least in part, for the decreased invasiveness of these cells.
Whereas E-cadherin increases would be associated with a mesenchymal-
to-epithelial transition, the two NSCLC examined normally express
epithelial markers, and it is unlikely that the relatively modest changes
in E-cadherin expression in response to either rosiglitazone or Snail
silencing are sufficient to account for the structural changes observed
in three-dimensional culture. Alterations in other genes associated with
EMT are likely. Experiments using expression profiling of these cells
will better define these changes. The effects of rosiglitazone on COX-2
expression also seem to be mediated through Snail because cells si-
lenced for Snail have lower levels of COX-2. Inhibition of COX-2
has been shown to inhibit anchorage-independent growth in NSCLC
[41]. Snail has not been shown to directly regulate the COX-2 promoter,
but earlier works from our laboratory and others’ have demonstrated
COX-2 suppression through either nuclear factor-κB [26] or AP-1
regulation [42].
Suppression of Snail is mediated through the inhibition of tran-
scriptional control, as evidenced by lower levels of mRNA and de-
creased Snail promoter activity after rosiglitazone stimulation. Although
the direct effectors of PPARγ mediating this effect are not clearly
defined, our data support a role for the MEK-1/2/ERK family of
MAPKs in mediating Snail suppression. Rosiglitazone decreased ERK
activity in both cell lines, and a specific MEK inhibitor mimicked
the effects of rosiglitazone on Snail expression. The slow time course
of ERK inhibition suggests that the effects of rosiglitazone are me-
diated through altered gene transcription, consistent with the role of
PPARγ as a ligand-activated transcription factor. A potential mecha-
nism would be the increased expression of a protein phosphatase
that would counteract the effects of MEK phosphorylation of ERK.
Global expression profiling of NSCLC overexpressing PPARγ indi-
cates increased expression of multiple protein phosphatases. Although
we have examined the expression of DUSP4 and 6, as well as MAPK
phosphatase-1 in response to rosiglitazone, to date we have not identi-
fied a candidate phosphatase that would mediate the ERK inhibition.
Similar regulation of Snail expression has recently been reported in
breast cancer, where inhibition of the ERK pathway blocks the induc-
tion of Snail by TrkB [43].
Our observations are consistent with other studies analyzing the
effects of Snail silencing in various other types of cancer. Snail silencing
in mouse skin carcinoma cell lines induces a more differentiated, less
invasive phenotype with a significant reduction in their tumorigenic
capacity [8]. Snail knockdown also dramatically affects tumor growth
and lymph node metastasis of human breast carcinoma cells [8]. It
has been reported that Slug cooperates with Snail in tumor growth po-
tential of mouse skin carcinoma cells and in the generation of lung and
liver metastasis [8]. A recent study has also implicated ZEB1 as being
critical for suppression of the tumor suppressor Semaphorin 3F [19].
Thus, distinct members of the Snail family may participate through both
overlapping and nonoverlapping pathways to affect cancer cell growth
and metastasis.
In conclusion, this study demonstrates that suppression of Snail is
both necessary and sufficient for many of the responses to rosiglitazone
in these cell lines. Both of these cell lines are adenocarcinoma cells har-
boring oncogenic K-Ras mutations. They are also “epithelial-like” and
represent K-Ras–dependent cell lines [44]. It will be important to de-
termine whether Snail plays a comparable role in the responses of other
classes of NSCLC to PPARγ activators. This information will be critical
in developing novel therapeutic agents targeting Snail as well as in the
selection of patients for clinical trials with PPARγ activators.
Figure 6. PPARγ effects on Snail expression are mediated by sup-
pressing ERK phosphorylation. (A) NSCLC were grown in the pres-
ence of absence of rosiglitazone (10 μM) for the indicated times. Cell
lysates were immunoblotted for ERK and phospho-ERK. β-Actin was
used as loading control. (B) Cells were treatedwith PD98059 (20 μM)
or rosiglitazone (10 μM), either alone or in combination, along with
appropriate controls (0.1% DMSO). Nuclear extracts were immuno-
blotted for Snail. Levels of β-actin were used as a loading control.
Results are representative of three independent experiments.
Figure 5. Snail overexpression blocks the biological responses to Rosiglitazone. (A) Colony formation in soft agar (top panels), cell migration
(middle panels), or invasion (bottom panels) was determined for the indicated cell lines transfected with empty vector (L1 and L4 for H2122
and L2 and L5 for H2009) or individual clones overexpressing Snail (S8 and S9 for H2122 and S1 and S9 for H2009) treated with rosiglitazone
(10 μM) or vehicle (0.1%DMSO). **P< .01 versus empty vector controls, ***P< .001 versus empty vector controls; *P< .05 versus empty
vector controls. (B) MMP-9 and MMP-2 mRNA was quantified in the indicated cells by quantitative RT-PCR. *P < .05 versus empty vector
controls, **P< .01 versus empty vector controls. (C) The indicated cells were grown for 7 days in three-dimensional Matrigel culture in the
presence or absence of rosiglitazone (10 μM). After 7 days in culture, structures were fixed and stained for E-cadherin (green). Represen-
tative acinar structures are shown.
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Figure W1. Pharmacological inhibition of PPARγ reverses effects of rosiglitazone on Snail mRNA levels. H2122 cells were exposed for
24 hours to either 10 μM rosiglitazone (Rosi), T007 (10 μM), the combination of Rosi + T007, or vehicle (0.1% DMSO). Total RNA was
isolated and levels of Snail mRNA quantitated by quantitative RT-PCR. Results shown represent the mean of three independent experi-
ments. Rosi decreased Snail mRNA levels, and this was completely reversed by exposure to T007. *P < .05 versus control.
Figure W2. Suppression of Snail by PPARγ is independent of GSK-3β. (A) H2122 or H2009 cells were stimulated for 24 hours with 10 μM
rosiglitazone. Cell extracts were prepared in MAPK lysis buffer and immunoblotted for p-GSK-3β and GSK-3β. Levels of β-actin were used as
a loading control. Results are representative of three independent experiments. (B) Cells were treated with GSK-3 β inhibitor (10 μM) or
rosiglitazone (10 μM), either alone or in combination, along with appropriate controls (0.1% DMSO). Extracts were prepared as described
in Materials and Methods and immunoblotted for Snail. Levels of β-actin were used as a loading control. Results are representative of
three independent experiments.
